Pure mutated DDR2 without evidence of an altered copy number was reported in a few malignancies including 13.8% of cutaneous squamous cell carcinomas [38], 6.9% of small cell lung cancers [39], 4.5% of uterine carcinosarcomas [40], and 4.1% of cutaneous melanomas [41]. This evidence concerns the gene DDR2 and uterine carcinosarcoma.